Cyteir Therapeutics — Investor Day (April 2022)
39 slides from Cyteir Therapeutics's investor day presentation, Apr 26, 2022
Slide 1: Virtual R&D Day April 26, 2022
Virtual R&D Day April 26, 2022 ®
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” regarding Cyteir’s clinical and pre-clinical development, market opportunity, and expected future performance. Forward-looking statements include statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “
Slide 3: Agenda
Agenda Introduction Markus Renschler, MD – President and CEO Discovery of the Mechanism of Action of CYT-0851 Paul Secrist, PhD – Chief Scientific Officer Translating the Science into Our Clinical Strategy Judd Englert, MD, PhD - SVP, Clinical Research & Development Q&A Summary and Upcoming Mileston
Slide 4: CYT-0851 Has Monotherapy Activity in Multiple Tumor Types
CYT-0851 Has Monotherapy Activity in Multiple Tumor Types Baseline Month 12 Baseline Month 3 Baseline Month 6 Complete Response (treated for 16+ months) Partial Response (treated for 6 months) Unconfirmed Partial Response (treated for 11 months) Diffuse Large B-Cell Lymphoma Sarcoma Follicular Lymph
Slide 5: Executive Summary
Executive Summary CYT-0851 is advancing in six monotherapy Phase 2 cohorts and three combination therapy Phase 1 cohorts Recent molecular, bioinformatic, and biochemical characterization led to the discovery that the observed effects of CYT-0851 are due to inhibition of monocarboxylate transporters,
Slide 6: Cyteir Therapeutics' Drug Candidate Pipeline
Cyteir Therapeutics’ Drug Candidate Pipeline Combination therapy in solid tumors and hematologic malignancies Monotherapy in solid tumors and hematologic malignancies CYT-0851 (MCT) Phase 1/2 Pivotal** Worldwide Rights Status Indications* Preclinical Solid tumors and hematologic malignancies CYT-185
Slide 7: Discovery of the Mechanism of Action of CYT-0851
Discovery of the Mechanism of Action of CYT-0851
Slide 8: CYT-0851 Discovered Using Phenotypic Screen and Advanced Rapidly to Clinic
CYT-0851 Discovered Using Phenotypic Screen and Advanced Rapidly to Clinic Phenotypic screening strategy exploiting novel synthetic lethality between AID expression and inhibition of DNA repair AID: activation-induced cytidine deaminase; PD: pharmacodynamic; γH2AX: marker of damaged DNA Viable Letha
Slide 9: Bioinformatics Approach to Discovering the Molecular Target of CYT-0851
Bioinformatics Approach to Discovering the Molecular Target of CYT-0851 Develop target hypotheses by combining CYT-0851 sensitivity data with gene essentiality data Strengthen target hypotheses by combining CYT-0851 sensitivity data with gene expression data Explore/confirm target biology using geno
Slide 10: Bioinformatics Approach to Discovering the Molecular Target of CYT-0851
Bioinformatics Approach to Discovering the Molecular Target of CYT-0851 Develop target hypotheses by combining CYT-0851 sensitivity data with gene essentiality data Genetic deletion of which genes best mimic treatment with CYT-0851? CYT-0851 Sensitivity Data Genome-wide Gene Essentiality Data (>16,0
Slide 11: Deletion of MCT1 Most Closely Mimicked Treatment with CYT-0851
Deletion of MCT1 Most Closely Mimicked Treatment with CYT-0851 Genetic deletion of which gene best mimicked treatment with CYT-0851? Answer: Monocarboxylate Transporter 1 (MCT1) MCT1 #1 correlated gene out of 16,000+ genes CYT-0851 Sensitivity Data Genome-wide Gene Essentiality Data (>16,000 genes)
Slide 12: What are Monocarboxylate Transporters and What Do They Do?
What are Monocarboxylate Transporters and What Do They Do? Monocarboxylate transporters (MCTs) are a family of proteins that bi-directionally transport key metabolic intermediates such as lactate, pyruvate, and ketone bodies MCT1 is a high affinity lactate transporter, efficiently imports and export
Slide 13: Bioinformatics Approach to Discovering the Molecular Target of CYT-0851
Bioinformatics Approach to Discovering the Molecular Target of CYT-0851 Genetic deletion of which gene best mimicked treatment with CYT-0851? Answer: Monocarboxylate Transporter 1 (MCT1) MCT1 Strengthen target hypotheses by combining CYT-0851 sensitivity data with gene expression data Explore/confir
Slide 14: MCT4 Expression Strongly Correlated with Resistance to CYT-0851
MCT4 Expression Strongly Correlated with Resistance to CYT-0851 Genetic deletion of which gene best mimicked treatment with CYT-0851? Answer: Monocarboxylate Transporter 1 (MCT1) MCT1 Expression of which gene best correlated with resistance to CYT-0851? Answer: Monocarboxylate Transporter 4 (MCT4) M
Slide 15: Bioinformatics Approach to Discovering the Molecular Target of CYT-0851
Bioinformatics Approach to Discovering the Molecular Target of CYT-0851 Genetic deletion of which gene best mimicked treatment with CYT-0851? Answer: Monocarboxylate Transporter 1 (MCT1) MCT1 Expression of which gene best correlated with resistance to CYT-0851? Answer: Monocarboxylate Transporter 4
Slide 16: MCT4 Gene Deletion Increased Sensitivity to CYT-0851
MCT4 Gene Deletion Increased Sensitivity to CYT-0851 Genetic deletion of which gene best mimicked treatment with CYT-0851? Answer: Monocarboxylate Transporter 1 (MCT1) MCT1 Expression of which gene best correlated with resistance to CYT-0851? Genetic deletion of which genes improved sensitivity to C
Slide 17: Experimental Confirmation that CYT-0851 Inhibits MCT Transporter Activity
Experimental Confirmation that CYT-0851 Inhibits MCT Transporter Activity MCT1-mediated substrate import inhibition MCT: monocarboxylate transporter MCT-mediated lactate export inhibition Multiple lactate transporter assays corroborate that CYT-0851 is a nanomolar inhibitor of MCT activity
Slide 18: Cancer Metabolism and the Importance of Lactate Transport
Cancer Metabolism and the Importance of Lactate Transport
Slide 19: What is Cancer Metabolism and Why is Lactate Transport Important?
What is Cancer Metabolism and Why is Lactate Transport Important? ATP: adenosine triphosphate; TCA: tricarboxylic acid cycle Cancer cells must rewire their metabolism to support a higher replication rate and out-compete normal cells Too much intracellular lactate is cytotoxic - cancer cells become d
Slide 20: MCT-Mediated Lactate Transport is Essential for Tumor Survival
MCT-Mediated Lactate Transport is Essential for Tumor Survival
Slide 21: CYT-0851 Inhibits Lactate Transport and Cancer Cell Metabolism
CYT-0851 Inhibits Lactate Transport and Cancer Cell Metabolism CYT-0851 treatment rapidly elevates intracellular lactate Result: impairs glycolysis via negative feedback and induces cell death via lactate toxicity CYT-0851 treatment rapidly reduces extracellular acidification Result: makes environme
Slide 22: Cytotoxicity of CYT-0851 Correlates with Ability to Inhibit Lactate Transport
Cytotoxicity of CYT-0851 Correlates with Ability to Inhibit Lactate Transport Intracellular lactate accumulation and cytotoxicity correlation is observed across a variety of cancer cell lines Lactate/cytotoxicity correlation in Daudi Burkitt’s lymphoma cell line Lactate/cytotoxicity correlation exis
Slide 23: Therapeutic Opportunity and Differentiation
Therapeutic Opportunity and Differentiation
Slide 24: MCT Inhibitor Landscape
MCT Inhibitor Landscape Company Cyteir AstraZeneca Bayer Nirogy MCT Selectivity MCT1 confirmed MCT2/3/4 pending MCT1 MCT1 MCT1+MCT4 Clinical Proof of Concept Lymphoma Solid tumors Lymphoma NA NA Current Status Phase 2 Phase 1 Preclinical Preclinical CYT-0851 In preliminary preclinical evaluation, CY
Slide 25: From Phenotype to Genotype: Mechanism of Action Summary
From Phenotype to Genotype: Mechanism of Action Summary CYT-0851 was discovered through a phenotypic screen with the hypothesis that it impaired DNA repair through RAD51 inhibition Using a bioinformatics approach and employing genome-wide CRISPR screening, CYT-0851 was identified as an MCT inhibitor
Slide 26: Translating the Science into Our Clinical Strategy
Translating the Science into Our Clinical Strategy
Slide 27: Mechanism Supports Our Broad Clinical Plan for CYT-0851
Mechanism Supports Our Broad Clinical Plan for CYT-0851 Early monotherapy responses observed in multiple tumor types MCT transporter activity is fundamental to the survival and growth of many cancers Current trial design allows for additional cohorts to expand development opportunities Scientific li
Slide 28: MCT1 Expression Predicts Poor Prognosis in Cancer
MCT1 Expression Predicts Poor Prognosis in Cancer Soft-tissue Sarcoma Multiple Myeloma Breast Cancer Non-Small Cell Lung Cancer Pinheiro, C., et al. J Transl Med 12, 118 (2014) Stroh, J., et al. Blood Advances 6, 2 (2022) Hong, C., et al. Cell Reports 14, 7 (2016) MCT1 negative MCT1 positive Hong, C
Slide 29: Mechanism Further Supports Current Clinical Development Plan
Mechanism Further Supports Current Clinical Development Plan Phase 1 Monotherapy | Initiated Sep 2019 Phase 2 Monotherapy | Initiated Jan 2022 6 Expansion cohorts Signal seeking/POC Hematologic Malignancies DLBCL Follicular lymphoma Multiple myeloma Potential registration-oriented development CYT-08
Slide 30: New Mechanistic Understanding Sharpens Our Scientific Focus
New Mechanistic Understanding Sharpens of our Scientific Focus Patient Selection Biomarkers Pharmacodynamic Biomarkers Rational Combinations +
Slide 31: Refining our Patient Enrichment Strategy
Refining our Patient Enrichment Strategy Sensitive tumors hypothesized to be those hard-wired to utilize glycolysis and export large amounts of lactate Exploring whether imaging techniques, such as FDG-PET, that identify glycolytic tumors will enrich for responders Developing MCT1 and MCT4 protein e
Slide 32: Combination Treatments Exploiting Synthetic Lethality with CYT-0851
Combination Treatments Exploiting Synthetic Lethality with CYT-0851 TYMS CRISPR screen identified genetic deletion of thymidylate synthase (TYMS), the molecular target of 5-fluorouracil, as synthetically lethal with CYT-0851 Identify Validate Confirm Combining CYT-0851 and 5-FU (Fluorouracil) overco
Slide 33: Combination Strategies to Chemically Induce Synthetic Lethality with CYT-0851
Combination Strategies to Chemically Induce Synthetic Lethality with CYT-0851 Opens Expansive Markets Phase 1 Combination | Initiated Dec 2021 CYT-0851 + Rituximab + Bendamustine Non-Hodgkin Lymphoma Phase 2 Combination | 2023 DLBCL Follicular lymphoma Dose-Finding Potential Cancers for Dose-Confirm
Slide 34: Clinical Summary: Broad Applicability Across Cancers with First-in-Class Potential
Clinical Summary: Broad Applicability Across Cancers with First-in-Class Potential CYT-0851 has demonstrated durable monotherapy activity across multiple tumor types with a generally favorable tolerability in Phase 1 Tumor indications previously selected for Phase 2 are supported by the new mechanis
Slide 35: Summary
° Summary err “fe? - > a
Slide 36: Completing the CYT-0851 Drug Development Puzzle
Completing the CYT-0851 Drug Development Puzzle MCT Inhibition Lack of myelosuppression Biomarkers New understanding provides an opportunity to accelerate biomarker development and to expand market opportunities to complete the puzzle MCT selectivity Rational combinations Additional tumor types Syne
Slide 37: CYT-0851 Future Milestones
CYT-0851 Future Milestones 2022 Dose first patient in the Phase 1 CYT-0851 combination trial Dose first patient in the Phase 2 CYT-0851 monotherapy expansion trial Present data from Phase 1 CYT-0851 dose escalation trial Safety data from Phase 1 CYT-0851 combination trial Complete stage 1 of CYT-085
Slide 38: Summary: Scientific Innovation Driving Clinical Strategy
Summary: Scientific Innovation Driving Clinical Strategy YT Since IPO in June 2021, completed CYT-0851 Phase 1 trial , opened Phase 1 combination therapy trial (3 regimens), opened Phase 2 monotherapy trial (6 cohorts) and elucidated CYT-0851 MOA CYT-0851 has potential to be first-in-class MCT inhib
Slide 39: Thank You for Attending
THANK YOU FOR ATTENDING